Bonraybio CoTPE:6955 65 Altman Z-Score is 24.94 as of Jul. 07, 2026, which is 17% below its 10-year median of 30.15. GuruFocus rates TPE:6955 with a GF Score™ of 65/100 and a GF Value™ of NT$184.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Bonraybio Co ranks better than 94.68% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 24.94 is strong.
Bonraybio Co has a Altman Z-Score of 24.94, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Bonraybio Co's Altman Z-Score or its related term are showing as below:
TPE:6955'
s Altman Z-Score Range Over the Past 10 Years
Min: 23.6 Med: 30.15 Max: 39.76
Current: 24.94
During the past 6 years, Bonraybio Co's highest Altman Z-Score was 39.76. The lowest was 23.60. And the median was 30.15.
Bonraybio Co (TPE:6955) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Bonraybio Co Altman Z-Score Related Terms
Bonraybio Co Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Bonraybio Co's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6955 vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, Bonraybio Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonraybio Co Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonraybio Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Bonraybio Co's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Bonraybio Co's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8003
+
1.4
*
0.1566
+
3.3
*
0.1457
+
0.6
*
38.0863
+
1.0
*
0.4255
=
24.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Bonraybio Co (TPE:6955) has a Altman Z-Score of 24.94 as of Jul. 07, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Bonraybio Co and its competitors. This is 17% below median its historical median of 30.15. Over the past decade, Bonraybio Co's Altman Z-Score has ranged from 23.60 to 39.76. According to the industry distribution chart, Bonraybio Co ranks #43 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is Bonraybio Co's Altman Z-Score too high?
Bonraybio Co's current Altman Z-Score of 24.94 is 17% below median its 10-year median of 30.15. Over the past 10 years, this metric has ranged from a low of 23.60 to a high of 39.76. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. Bonraybio Co's value of 24.94 is 725.8% above this industry median. Based on the distribution chart, Bonraybio Co ranks #43 out of 809 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonraybio Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonraybio Co's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bonraybio Co ranks #43 out of 809 companies for Altman Z-Score. This places Bonraybio Co in the top 5% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.02. Bonraybio Co's value of 24.94 is 725.8% above this benchmark. Historically, Bonraybio Co's own Altman Z-Score has ranged from 23.60 to 39.76 over the past decade. While the company's 10-year median is 30.15 vs. the industry median of 3.02, Bonraybio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonraybio Co's current Altman Z-Score of 24.94 is 725.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Bonraybio Co and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonraybio Co's current Altman Z-Score is 24.94, which is 17% below median its own 10-year median of 30.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonraybio Co stock overvalued right now?
Based on GuruFocus' analysis, Bonraybio Co (TPE:6955) is currently considered Possible Value Trap. The stock's GF Value™ is NT$184.74, compared to a current price of NT$120.50 — trading 34.8% below its estimated fair value. The current Altman Z-Score is 24.94, which is 17% below median its 10-year median of 30.15 and 725.8% above the Medical Devices & Instruments industry median of 3.02. Bonraybio Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Bonraybio Co (TPE:6955), the current Altman Z-Score is 24.94 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonraybio Co (TPE:6955) Overvalued in 2026?
Based on GuruFocus' analysis, Bonraybio Co stock appears to be undervalued.
The current stock price of NT$120.50 is trading 34.8% below its estimated GF Value™ of NT$184.74.
GuruFocus considers Bonraybio Co to be Possible Value Trap.
Key valuation signals for TPE:6955:
Altman Z-Score: 24.94 (17% below median its 10-year median of 30.15)
GF Value™: NT$184.74 vs. price of NT$120.50 (34.8% below fair value)
Industry Position: 725.8% above the Medical Devices & Instruments median (#43 of 809)
No single metric tells the full story. See the TPE:6955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonraybio Co Ltd engages in research, development, and manufacturing of vitro diagnostic devices. The firm produces semen quality analyzers and Semen Analysis Systems for the clinic.
65GF Score
Get the complete analysis for TPE:6955
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6955 has been successfully added to your 
